Federal regulators have agreed to review a Swiss pharmaceutical company's applications for two cheaper generic versions of ...
Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court ...
On June 16, 2026, the Centers for Medicare & Medicaid Services (CMS) published a proposed rule that would codify the Medicare Drug Price ...
The National Healthcare Security Administration said on Monday that 557 drugs have passed the preliminary review for ...
When life sciences startups think about patent strategy, the natural instinct is to focus on the core science — the novel compound, the ...
On July 6th, Sen. Jim Banks (R-Ind.) sent a letter to Commerce Secretary Howard Lutnick urging the U.S. Patent and Trademark ...
Health advocacy groups have urged the government to reject TRIPS-plus provisions in Thailand's free trade negotiations with the European Union (EU), warning they could delay access to generic ...
Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
A successful closure of a US FDA inspection is generally viewed positively by investors as it removes a key regulatory overhang ...
In corporate management, nothing is more daunting than uncertainty, not even loss itself. If the scale of a loss can be predicted, countermeasures can ...
Indian companies filed 184 Type II DMFs with the US FDA in Q1 2026 against China's 149, reinforcing the country's leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results